Ascletis Pharma (China) Co., Limited Clinical Trial Pipeline: 4 Active Trials, 4 Changes This Month

4

Active Trials

3

Recruiting

2

Phase 3

4

Disease Areas

4

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-08-15	NCT07743450 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Recruitment opened
2026-08-15	NCT07743450 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Trial sites expanded: 0 -> 136 locations
2026-08-15	NCT07743463 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Recruitment opened
2026-08-15	NCT07743463 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Trial sites expanded: 0 -> 120 locations

New Trial Filings, Last 30 Days

First Posted	Trial	Phase	Status
2026-08-03	NCT07743450 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Phase 3	Recruiting
2026-08-03	NCT07743463 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Phase 3	Recruiting

Active Trials by Phase

Phase 3

2

Phase 2

1

Phase 1

1

Active Trials

NCT ID	Title	Condition	Status
Phase 3
NCT07743450	A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Obesity	Recruiting
NCT07743463	A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult…	Obesity	Recruiting
Phase 2
NCT07321678	A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in…	T2DM (Type 2 Diabetes Mellitus)	Active, Not Recruiting
Phase 1
NCT07024602	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and…	Plaque Psoriasis	Recruiting

Disease Areas

Get alerts when Ascletis Pharma (China) Co., Limited's trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.